Antithymocyte Globulin Versus Interleukin-2 Receptor Antagonist in Kidney Transplant Recipients With Hepatitis C Virus
Conclusions.
Our findings suggest that ATG, as compared to IL2RA, may lower the risk of acute rejection without increasing hepatic complications in HCV+ KT recipients. Given the higher rates of acute rejection in this population, ATG appears to be safe and reasonable for HCV+ recipients.
Source: Transplantation - Category: Transplant Surgery Tags: Original Clinical Science—General Source Type: research
More News: Cirrhosis | Hepatitis | Hepatitis C | Kidney Transplant | Kidney Transplantation | Liver | Liver Transplant | Medicare | Transplant Surgery | Transplants | Urology & Nephrology